Differences in Demographic and Clinical Profiles Among Patients Adherent Vs. Non-Adherent to Revefenacin Following a COPD-Related Hospitalization
Author(s)
Grace Leung, MPH1, Lauren Cochran, PharmD2, Melinda K. Lacy, PharmD2, Joseph Cook, JD, PhD3, Kim Gilchrist, MBA, MD3, Donna McMorrow, BS4, Ilya Okunev, MA4, Joseph Tkacz, MS4;
1Zavicus Consulting LLC, Hillsborough, CA, USA, 2Theravance Biopharma, South San Francisco, CA, USA, 3Viatris, Inc., Canonsburg, PA, USA, 4Inovalon, Bowie, MD, USA
1Zavicus Consulting LLC, Hillsborough, CA, USA, 2Theravance Biopharma, South San Francisco, CA, USA, 3Viatris, Inc., Canonsburg, PA, USA, 4Inovalon, Bowie, MD, USA
OBJECTIVES: To assess the real-world adherence rate to revefenacin prescribed post-COPD hospitalization discharge and to characterize patients adherent versus nonadherent to treatment.
METHODS: The 100% Medicare Fee-for-Service and MORE2 Registry of closed claims databases were leveraged for analyses. Study inclusion criteria were as follows: 1) COPD-related hospitalization between 11/9/2018 and 9/30/2023, 2) prescribed revefenacin (index date) within 14 days post-discharge, 3) aged ≥40 years on index, and 4) continuous enrollment for ≥12 months preceding (baseline) and ≥90 days following index. The proportion of days covered (PDC) with revefenacin was computed to create adherent (PDC ≥ 0.80) and non-adherent (PDC < 0.80) cohorts. Clinical characteristics were assessed during the 12-month baseline period, while demographics were assessed on index. Descriptive and comparative analyses were conducted to assess differences in patient profiles between adherent vs. non-adherent patients.
RESULTS: A total of 687 patients qualified for the study, 313 adherent (45.6%) and 374 non-adherent (54.4%). Compared to non-adherent patients, adherent patients were older (74.4±9.6 vs. 72.9±9.3, p <0.05), more likely to be White (90.4% vs. 83.7%, p <0.05), and more likely to be ineligible for a Medicare Part D low-income subsidy (67.7% vs. 57.0%, p <0.05). Additionally, adherent patients had statistically significant (p < 0.05) lower rates of congestive heart disease (46.3% vs. 55.4%), diabetes with complications (18.9% vs. 23.5%), anxiety (45.1% vs. 58.0%), depression (39.0% vs. 48.1%), and asthma (25.2% vs. 32.1%); though numerically higher (p>0.05) rates of COPD therapy utilization including inhaled corticosteroids+long-acting beta-agonist, short-acting beta-agonist, leukotriene modifiers, and oxygen therapy, versus non-adherent patients.
CONCLUSIONS: Demographic and clinical differences were observed between patients adherent vs. non-adherent to revefenacin post COPD hospitalization. This is the first real world study observing adherence on revefenacin prescribed after a recent COPD hospitalization, and highlights potential age, racial and socioeconomic disparities that present opportunities to improve medication adherence.
METHODS: The 100% Medicare Fee-for-Service and MORE2 Registry of closed claims databases were leveraged for analyses. Study inclusion criteria were as follows: 1) COPD-related hospitalization between 11/9/2018 and 9/30/2023, 2) prescribed revefenacin (index date) within 14 days post-discharge, 3) aged ≥40 years on index, and 4) continuous enrollment for ≥12 months preceding (baseline) and ≥90 days following index. The proportion of days covered (PDC) with revefenacin was computed to create adherent (PDC ≥ 0.80) and non-adherent (PDC < 0.80) cohorts. Clinical characteristics were assessed during the 12-month baseline period, while demographics were assessed on index. Descriptive and comparative analyses were conducted to assess differences in patient profiles between adherent vs. non-adherent patients.
RESULTS: A total of 687 patients qualified for the study, 313 adherent (45.6%) and 374 non-adherent (54.4%). Compared to non-adherent patients, adherent patients were older (74.4±9.6 vs. 72.9±9.3, p <0.05), more likely to be White (90.4% vs. 83.7%, p <0.05), and more likely to be ineligible for a Medicare Part D low-income subsidy (67.7% vs. 57.0%, p <0.05). Additionally, adherent patients had statistically significant (p < 0.05) lower rates of congestive heart disease (46.3% vs. 55.4%), diabetes with complications (18.9% vs. 23.5%), anxiety (45.1% vs. 58.0%), depression (39.0% vs. 48.1%), and asthma (25.2% vs. 32.1%); though numerically higher (p>0.05) rates of COPD therapy utilization including inhaled corticosteroids+long-acting beta-agonist, short-acting beta-agonist, leukotriene modifiers, and oxygen therapy, versus non-adherent patients.
CONCLUSIONS: Demographic and clinical differences were observed between patients adherent vs. non-adherent to revefenacin post COPD hospitalization. This is the first real world study observing adherence on revefenacin prescribed after a recent COPD hospitalization, and highlights potential age, racial and socioeconomic disparities that present opportunities to improve medication adherence.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR22
Topic
Patient-Centered Research
Disease
SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)